Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius

(2011) G. Socie et al.   BLOOD

Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans

(2011) M. Srinivasan et al.   BLOOD

Rituximab Administration within 6 Months of T Cell-Depleted Allogeneic SCT is Associated with Prolonged Life-Threatening Cytopenias

(2010) Zachariah McIver et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation and Antithymocyte Globulin Preparative Regimen

(2010) Joanna M. Schaenman et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia

(2010) Z. Kuzmina et al.   BLOOD

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

(2010) P. Dreger et al.   BLOOD

Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia

(2010) Carol D. Jones et al.   BRITISH JOURNAL OF HAEMATOLOGY

Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study

(2010) S. J. Kim et al.   HAEMATOLOGICA

Rituximab Treatment before Reduced-Intensity Conditioning Transplantation Associates with a Decreased Incidence of Extensive Chronic GVHD

(2009) Suzanne van Dorp et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors

(2009) H. E. Kohrt et al.   BLOOD

The role of B cells in the pathogenesis of graft-versus-host disease

(2009) A. Shimabukuro-Vornhagen et al.   BLOOD

Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease

(2009) S. Sarantopoulos et al.   BLOOD

Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation

(2009) Voravit Ratanatharathorn et al.   BRITISH JOURNAL OF HAEMATOLOGY

Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells

(2008) B. E. Anderson et al.   BLOOD

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

Rituximab as salvage therapy for refractory chronic GVHD

(2008) M Mohty et al.   BONE MARROW TRANSPLANTATION

Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning

(2008) Mohamed L. Sorror et al.   JOURNAL OF CLINICAL ONCOLOGY